Topical treatments for blepharokeratoconjunctivitis in children

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 2, 2017, Pages

  O'Gallagher, Michael ^a   Bunce, Catey ^b   Hingorani, Melanie ^a   Larkin, Frank ^a   Tuft, Stephen ^a   Dahlmann Noor, Annegret ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ARTIFICIAL TEAR; CHLORAMPHENICOL; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LOTEPREDNOL; LOTEPREDNOL ETABONATE; LOTEPREDNOL ETABONATE PLUS TOBRAMYCIN; MACROLIDE; STEROID; TACROLIMUS; TOBRAMYCIN; ANTIALLERGIC AGENT; ANTIINFECTIVE AGENT;

BLEPHAROCONJUNCTIVITIS; CHILD; CONJUNCTIVITIS; DRUG EFFICACY; DRUG SAFETY; EYE DISCHARGE; EYE INFLAMMATION; EYE PAIN; HUMAN; KERATOCONJUNCTIVITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TOPICAL TREATMENT; TREATMENT OUTCOME; VISUAL ACUITY; BLEPHARITIS; CONJUNCTIVA; EYELID; INFANT; MICROBIOLOGY; NEWBORN; PRESCHOOL CHILD; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTI-ALLERGIC AGENTS; ANTI-BACTERIAL AGENTS; BLEPHARITIS; CHILD; CHILD, PRESCHOOL; CONJUNCTIVA; EYELIDS; HUMANS; INFANT; INFANT, NEWBORN; KERATOCONJUNCTIVITIS; LOTEPREDNOL ETABONATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOBRAMYCIN;

EID: 85011835473     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011965.pub2     Document Type: Review

References (79)

1. Comstock TL, Paterno MR, Bateman KM, DeCory HH, Gearinger M. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs 2012;14(2):119-30. [4496545]
2. Bloom PA, Leeming JP, Power W, Laidlaw DA, Collum LM, Easty DL. Topical ciprofloxacin in the treatment of blepharitis and blepharoconjunctivitis. European Journal of Ophthalmology 1994;4(1):6-12. [4496547]
3. Chen M, Gong L, Sun X, Gu Y, He X, Qu J, et al. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Current Medical Research and Opinion 2012;28(3):385-94. [4496549]
4. Hosseini K, Hutcheson J, Lindstrom RL. A Phase III clinical study to evaluate the efficacy of combined azithromycin and dexamethasone in the treatment of blepharoconjunctivitis. Clinical Ophthalmology 2013;7:2225-34. [4496551]
5. Shulman J, Koreman N, Hirshman M, Samson C, Trochelman L. A double-blind, comparative clinical trial of a new steroid, anti-infective ophthalmic ointment for chronic staphylococcal blepharoconjunctivitis. Ocular Therapy and Surgery 1982;1:192-7. [4496553]
6. White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Current Medical Research and Opinion 2008;24(1):287-96. [4496555]
7. Afandi B, Toumeh MS, Saadi HF. Cushing's syndrome caused by unsupervised use of ocular glucocorticoids. Endocrine Practice 2003;9(6):526-9.
8. Asbell PA, Stapleton FJ, Wickström K, Akpek EK, Aragona P, Dana R, et al. The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. Investigative Ophthalmology and Visual Science 2011;52(4):2065-85.
9. Auw-Hädrich C, Reinhard T. Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe 2009;106(7):635-8.
10. Bondalapati S, Cabrera MT. Sub-tenon triamcinolone acetonide injections for topical medication intolerance in chronic blepharokeratoconjunctivitis. Cornea 2014;33(9):999-1001.
11. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22(7):640-50.
12. Cehajic-Kapetanovic J, Kwartz J. Augmentin duo™ in the treatment of childhood blepharokeratoconjunctivitis. Journal of Pediatric Ophthalmology and Strabismus 2010;47(6):356-60.
13. Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Survey of Ophthalmology 2012;57(5):415-29.
14. Chiang MY, Sarkar M, Koppens JM, Milles J, Shah P. Exogenous Cushing's syndrome and topical ocular steroids. Eye 2006;20(6):725-7.
15. Choi DS, Djalilian A. Oral azithromycin combined with topical anti-inflammatory agents in the treatment of blepharokeratoconjunctivitis in children. Journal of AAPOS 2013;17(1):112-3.
16. Comstock TL, Holland EJ. Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens. Expert Opinion on Pharmacotherapy 2010;11(5):843-52.
17. Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. International Journal of Inflammation 2012;2012:789623. [DOI: 10.1155/2012/789623]
18. Deeks JJ, Higgins JP, Altman DG editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
19. Doan S, Gabison EE, Nghiem-Buffet S, Abitbol O, Gatinel D, Hoang-Xuan T. Long-term visual outcome of childhood blepharokeratoconjunctivitis. American Journal of Ophthalmology 2007;143(3):528-9.
20. Doan S, Gabison E, Chiambaretta F, Touati M, Cochereau I. Efficacy of azithromycin 1.5% eye drops in childhood ocular rosacea with phlyctenular blepharokeratoconjunctivitis. Journal of Ophthalmic Inflammation and Infection 2013;3:38.
21. Dougherty BE, Nichols JJ, Nichols KK. Rasch analysis of the Ocular Surface Disease Index (OSDI). Investigative Ophthalmology and Visual Science 2011;52(12):8630-5.
22. Elbaz U, Mireskandari K, Shen C, Ali A. Corneal fine needle diathermy with adjuvant bevacizumab to treat corneal neovascularization in children. Cornea 2015;34(7):773-7.
23. Elder MJ, Bernauer W. Monitoring of activity and progression in cicatrising conjunctivitis. Developments in Ophthalmology 1997;28:111-22.
24. Everett SL, Kowalski RP, Karenchak LM, Landsittel D, Day R, Gordon YJ. An in vitro comparison of the susceptibilities of bacterial isolates from patients with conjunctivitis and blepharitis to newer and established topical antibiotics. Cornea 1995;14(4):382-7.
25. Farpour B, McClellan KA. Diagnosis and management of chronic blepharokeratoconjunctivitis in children. Journal of Pediatric Ophthalmology and Strabismus 2001;38(4):207-12.
26. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocular Surface 2003;1(3):107-26.
27. Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O'Brien T, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science 2011;52(4):2050-64.
28. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 14 June 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
29. Gupta N, Dhawan A, Beri S, D'Souza P. Clinical spectrum of pediatric blepharokeratoconjunctivitis. Journal of AAPOS 2010;14(6):527-9.
30. Hamada S, Khan I, Denniston AK, Rauz S. Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology 2012;96(7):949-55.
31. Hamada S, Nischal K, Evans J. The activity and damage of blepharokeratoconjunctivitis in children. Journal of AAPOS 2013;17(1):e16.
32. Hammersmith KM, Cohen EJ, Blake TD, Laibson PR, Rapuano CJ. Blepharokeratoconjunctivitis in children. Archives of Ophthalmology 2005;123(12):1667-70.
33. Hammersmith KM. Blepharokeratoconjunctivitis in children. Current Opinion in Ophthalmology 2015;26(4):301-5.
34. Higgins JP, Deeks JJ editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
35. Higgins JP, Altman DG editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
36. Ismail AS, Taharin R, Embong Z. Topical cyclosporin as an alternative treatment for vision threatening blepharokeratoconjunctivitis: a case report. International Medical Case Reports Journal 2012;5:33-7.
37. Jones SM, Weinstein JM, Cumberland P, Klein N, Nischal KK. Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology 2007;114(12):2271-80.
38. Joseph MA, Kaufman HE, Insler M. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea 2005;24(4):417-20.
39. Kacmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010;117(3):576-84.
40. Klein JO. History of macrolide use in pediatrics. Pediatric Infectious Disease Journal 1997;16(4):427-31.
41. Krupin T, Mandell AI, Podos SM, Becker B. Topical corticosteroid therapy and pituitary-adrenal function. Archives of Ophthalmology 1976;94(6):919-20.
42. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Archives of Ophthalmology 2000;118(11):1489-96.
43. Li DQ, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Experimental Eye Research 2006;82(4):588-96.
44. Li DQ, Zhou N, Zhang L, Ma P, Pflugfelder SC. Suppressive effects of azithromycin on zymosan-induced production of proinflammatory mediators by human corneal epithelial cells. Investigative Ophthalmology and Visual Science 2010;51(11):5623-9.
45. Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD005556.pub2]
46. Luo L, Li DQ, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Investigative Ophthalmology and Visual Science 2004;45(12):4293-301.
47. Mehta JS, Sagoo MS, Tuft SJ. Subconjunctival crystals in paediatric blepharokeratoconjunctivitis. Acta Ophthalmologica Scandinavica 2006;84(4):557-8.
48. Meisler DM, Raizman MB, Traboulsi EI. Oral erythromycin treatment for childhood blepharokeratitis. Journal of AAPOS 2000;4(6):379-80.
49. Murphy BS, Sundareshan V, Cory TJ, Hayes D, Anstead MI, Feola DJ. Azithromycin alters macrophage phenotype. Journal of Antimicrobial Chemotherapy 2008;61(3):554-60.
50. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Investigative Ophthalmology and Visual Science 2011;52(4):1930-7.
51. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsuhota K, et al. The international workshop on meibomian gland dysfunction: executive summary. Investigative Ophthalmology and Visual Science 2011;52(4):1922-9.
52. O'Gallagher M, Banteka M, Bunce C, Larkin F, Tuft S, Dahlmann-Noor A. Systemic treatment for blepharokeratoconjunctivitis in children. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD011750.pub2]
53. Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006;25(2):171-5.
54. Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea 2012;31(12):1386-93.
55. Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clinical Ophthalmology 2013;7:1797-803.
56. Raskin EM, Speaker MG, Laibson PR. Blepharitis. Infectious Disease Clinics of North America 1992;6(4):777-87.
57. Ratcliffe J, Couzner L, Flynn T, Sawyer M, Stevens K, Brazier J, et al. Valuing Child Health Utility 9D health states with a young adolescent sample: a feasibility study to compare best-worst scaling discrete-choice experiment, standard gamble and time trade-off methods. Applied Health Economics and Health Policy 2011;9(1):15-27.
58. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
59. Robert PY, Adenis JP. Comparative review of topical ophthalmic antibacterial preparations. Drugs 2001;61(2):175-85.
60. Rodríguez-Garcia A, González-Godínez S, López-Rubio S. Blepharokeratoconjunctivitis in childhood: corneal involvement and visual outcome. Eye 2016;30(3):438-46.
61. Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. Journal of Ocular Pharmacology and Therapeutics 2006;22(1):47-53.
62. Sacchetti M, Baiardini I, Lambiase A, Aronni S, Fassio O, Gramiccioni C, et al. Development and testing of the quality of life in children with vernal keratoconjunctivitis questionnaire. American Journal of Ophthalmology 2007;144(4):557-63.
63. Sadrai Z, Hajrasouliha AR, Chauhan S, Saban DR, Dastjerdi MH, Dana R. Effect of topical azithromycin on corneal innate immune responses. Investigative Ophthalmology and Visual Science 2011;52(5):2525-31.
64. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy 2009;26(6):651-9.
65. Singer TR, Isenberg SJ, Apt L. Conjunctival anaerobic and aerobic bacterial flora in paediatric versus adult subjects. British Journal of Ophthalmology 1988;72(6):448-51.
66. Sotozono C, Ang LP, Koizumi N, Higashihara H, Ueta M, Inatomi T, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology 2007;114(7):1294-302.
67. Steelman J, Kappy M. Adrenal suppression and growth retardation from ocular corticosteroids. Journal of Pediatric Ophthalmology and Strabismus 2001;38(3):177-8.
68. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. Ophthalmology 2000;107(5):967-74.
69. Suzuki M, Massingale ML, Ye F, Godbold J, Elfassy T, Vallabhajosyula M, et al. Tear osmolarity as a biomarker for dry eye disease severity. Investigative Ophthalmology and Visual Science 2011;51(9):4557-61.
70. Suzuki T, Teramukai S, Kinoshita S. Meibomian glands and ocular surface inflammation. The Ocular Surface 2015;13(2):133-49.
71. Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. British Journal of Ophthalmology 2005;89(10):1363-7.
72. Teo L, Mehta JS, Htoon HM, Tan DT. Severity of pediatric blepharokeratoconjunctivitis in Asian eyes. American Journal of Ophthalmology 2012;153(3):564-70.e.1.
73. Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Investigative Ophthalmology and Visual Science 2011;52(4):2006-49.
74. Torkildsen GL, Cockrum P, Meier E, Hammonds WM, Silverstein B, Silverstein S. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Current Medical Research and Opinion 2011;27(1):171-8.
75. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Medical Care 2001;39(8):800-12.
76. Viswalingam M, Rauz S, Morlet N, Dart JK. Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology 2005;89(4):400-3.
77. Wolthers OD. Growth suppression caused by corticosteroid eye drops. Journal of Pediatric Endocrinology and Metabolism 2011;24(5-6):393-4.
78. Wong IB, Nischal KK. Managing a child with an external ocular disease. Journal of AAPOS 2010;14(1):68-77.
79. O'Gallagher M, Bunce C, Hingorani M, Larkin F, Tuft S, Dahlmann-Noor A. Topical treatments for blepharokeratoconjunctivitis in children. Cochrane Database of Systematic Reviews 2015, Issue 11. [DOI: 10.1002/14651858.CD011965]